A biotech company in British Columbia says it has developed an effective treatment for anyone who has been infected with COVID-19 and is currently applying for federal approval to use the product.
Following months of clinical trials, Vancouver-based SaNOtize says its nasal spray has been found to reduce COVID-19 levels by 95 percent within 24 hours, and more than 99 percent in under three days.
During testing, COVID-19 patients in Canada and the U.K. self-administered the nasal spray.
When treated quickly enough, the virus was killed before it could spread to the lungs, according to the startup.
Miller said using the spray could mean milder symptoms and a potentially quicker recovery for anyone with COVID-19.
The nasal spray contains nitric oxide, which is known to act as a disinfectant and is produced naturally in humans.
No one reported any side effects during the nasal spray’s trial phase.
The developers say it can be used worldwide, as an added layer of protection against COVID-19.
Testing also found the spray works against the COVID-19 variant B.1.1.7 that originated in the U.K.
SaNOtize is now seeking federal approval for emergency use of the nasal spray in the U.K. and Canada.
Ideally, they want their product available over-the-counter. Each bottle contains two months’ worth of doses and would retail for approximately $50.
The biotech firm also plans to run another set of clinical trials in the coming weeks, to prove the spray not only kills COVID-19 in the body but can also prevent people from contracting the virus.
This content is also available in: Tiếng Việt